Cancer Treatment Reviews
Volume 29, Issue 5 , Pages 371-387 , October 2003

Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation

  • Anita Gothelf

      Affiliations

    • Department of Oncology, Rigshospitalet, University of Copenhagen, Denmark
    • Corresponding Author InformationCorrespondence to: Julie Gehl, MD, Department of Oncology, S4B1, Herlev Hospital in University of Copenhagen, Herlev Ringvej 75, 2730 Herlev, Denmark. Tel.: +45-44884488; fax: +45-44533077
    • ,
  • Lluis M Mir

      Affiliations

    • UMR 8121 CNRS, Institut Gustave-Roussy, Villejuif Cedex, France
    • ,
  • Julie Gehl

      Affiliations

    • Department of Oncology, Herlev Hospital in Univeristy of Copenhagen Denmark

References 

  1. Heller R, Gilbert R, Jaroszeski MJ. Clinical applications of electrochemotherapy. Adv. Drug Deliv. Rev. 1999;35:119–129
  2. Heller R, Gilbert R, Jaroszeski MJ. Electrochemotherapy: an emerging drug delivery method for the treatment of cancer. Adv. Drug Deliv. Rev. 1997;26:185–197
  3. Mir LM, Banoun H, Paoletti C. Introduction of definite amounts of nonpermeant molecules into living cells after electropermeabilization: direct access to the cytosol. Exp. Cell Res. 1988;175:15–25
  4. Neumann E, Schaefer-Ridder M, Wang Y, et al.  Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J. 1982;1:841–845
  5. Teruel MN, Blanpied TA, Shen K, et al.  A versatile microporation technique for the transfection of cultured CNS neurons. J. Neurosci. Methods. 1999;93:37–48
  6. Gehl J, Skovsgaard T, Mir LM. Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs. Anticancer Drugs. 1998;9:319–325
  7. Belehradek J, Orlowski S, Ramirez LH, et al.  Electropermeabilization of cells in tissues assessed by the qualitative and quantitative electroloading of bleomycin. Biochim. Biophys. Acta. 1994;1190:155–163
  8. Jaroszeski MJ, Dang V, Pottinger C, et al.  Toxicity of anticancer agents mediated by electroporation in vitro. Anticancer Drugs. 2000;11:201–208
  9. Gehl J, Sørensen TH, Nielsen K, et al.  In vivo electroporation of skeletal muscle: threshold, efficacy and relation to electric field distribution. Biochim. Biophys. Acta. 1999;1428:233–240
  10. Engstrom PE, Persson BR, Salford LG. Studies of in vivo electropermeabilization by gamma camera measurements of (99m)Tc-DTPA. Biochim. Biophys. Acta. 1999;1473:321–328
  11. Sersa G, Cemazar M, Miklavcic D. Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum (II) in mice. Cancer Res. 1995;55:3450–3455
  12. Rols MP, Delteil C, Golzio M, et al.  In vivo electrically mediated protein and gene transfer in murine melanoma. Nat. Biotechnol. 1998;16:168–171
  13. Mir LM, Bureau MF, Gehl J, et al.  High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc. Natl. Acad. Sci. USA. 1999;96:4262–4267
  14. Heller R, Jaroszeski M, Atkin A, et al.  In vivo gene electroinjection and expression in rat liver. FEBS Lett. 1996;389:225–228
  15. Mir LM. Therapeutic perspectives of in vivo cell electropermeabilization. Bioelectrochemistry. 2001;53:1–10
  16. Orlowski S, Belehradek J, Paoletti C, et al.  Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs. Biochem. Pharmacol. 1988;37:4727–4733
  17. Mir LM, Belehradek M, Domenge C, et al.  Electrochemotherapy, a new antitumor treatment: first clinical trial. C. R. Acad. Sci. III. 1991;313:613–618
  18. Orlowski S, Mir LM. Cell electropermeabilization: a new tool for biochemical and pharmacological studies. Biochim. Biophys. Acta. 1993;1154:51–63
  19. Satkauskas S, Bureau MF, Puc M, et al.  Mechanisms of in vivo DNA electrotransfer: respective contributions of cell electropermeabilization and DNA electrophoresis. Mol. Ther. 2002;5:133–140
  20. Weaver JC. Electroporation: a general phenomenon for manipulating cells and tissues. J. Cell. Biochem. 1993;51:426–435
  21. Gehl J, Skovsgaard T, Mir LM. Vascular reactions to in vivo electroporation: characterization and consequences for drug and gene delivery. Biochim. Biophys. Acta. 2002;1569:51–58
  22. Mir LM, Orlowski S, Belehradek J, et al.  Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur. J. Cancer. 1991;27:68–72
  23. Rodriguez-Cuevas S, Barroso-Bravo S, Almanza-Estrada J, et al.  Electrochemotherapy in primary and metastatic skin tumors: phase II trial using intralesional bleomycin. Arch. Med. Res. 2001;32:273–276
  24. Gehl J, Geertsen PF. Efficient palliation of haemorrhaging malignant melanoma skin metastases by electrochemotherapy. Melanoma Res. 2000;10:585–589
  25. Allegretti JP, Panje WR. Electroporation therapy for head and neck cancer including carotid artery involvement. Laryngoscope. 2001;111:52–56
  26. Rols MP, Bachaud JM, Giraud P, et al.  Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Res. 2000;10:468–474
  27. Glass LF, Pepine ML, Fenske NA, et al.  Bleomycin-mediated electrochemotherapy of metastatic melanoma. Arch. Dermatol. 1996;132:1353–1357
  28. Heller R, Jaroszeski MJ, Glass LF, et al.  Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer. 1996;77:964–971
  29. Belehradek M, Domenge C, Luboinski B, et al.  Electrochemotherapy, a new antitumor treatment. First clinical phases I–II trial. Cancer. 1993;72:3694–3700
  30. Sersa G, Cufer T, Cemazar M, et al.  Electrochemotherapy with bleomycin in the treatment of hypernephroma metastasis: case report and literature review. Tumori. 2000;86:163–165
  31. Kubota Y, Mir LM, Nakada T, et al.  Successful treatment of metastatic skin lesions with electrochemotherapy. J. Urol. 1998;160:1426
  32. Heller R, Jaroszeski MJ, Reintgen DS, et al.  Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer. 1998;83:148–157
  33. Domenge C, Orlowski S, Luboinski B, et al.  Antitumor electrochemotherapy: new advances in the clinical protocol. Cancer. 1996;77:956–963
  34. Burian M, Formanek M, Regele H. Electroporation therapy in head and neck cancer. Acta. Otolaryngol. 2003;123(2):264–268
  35. Sersa G, Stabuc B, Cemazar M, et al.  Electrochemotherapy with cisplatin: the systemic antitumour effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases. Melanoma Res. 2000;10:381–385
  36. Sersa G, Stabuc B, Cemazar M, et al.  Electrochemotherapy with cisplatin: potentiation of local cisplatin antitumour effectiveness by application of electric pulses in cancer patients. Eur. J. Cancer. 1998;34:1213–1218
  37. Sersa G, Stabuc B, Cemazar M, et al.  Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients. Clin. Cancer Res. 2000;6:863–867
  38. Sersa G, Cemazar M, Rudolf Z, et al.  Adenocarcinoma skin metastases treated by electrochemotherapy with cisplatin combined with radiation. Radiol. Oncol. 1999;33:291–296
  39. Rebersek M, Cufer T, Rudolf Z, et al.  Electrochemotherapy with cisplatin of breast cancer tumor nodules in a male patient. Radiol. Oncol. 2000;34:357–361
  40. Gilbert RA, Jaroszeski MJ, Heller R. Novel electrode designs for electrochemotherapy. Biochim. Biophys. Acta. 1997;1334:9–14
  41. Gehl J, Skovsgaard T, Nielsen SL, Mir LM. Electroporation of muscle tissue in vivo in mice. Sensitivity investigated by uptake of 51-chrome EDTA. In: Proceedings of the American Association for Cancer Research, vol. 38, 1997
  42. Miklavcic D, Beravs K, Semrov D, et al.  The importance of electric field distribution for effective in vivo electroporation of tissues. Biophys. J. 1998;74:2152–2158
  43. Miklavcic D, Semrov D, Mekid H, et al.  A validated model of in vivo electric field distribution in tissues for electrochemotherapy and for DNA electrotransfer for gene therapy. Biochim. Biophys. Acta. 2000;1523:73–83
  44. Mir LM, Orlowski S. Mechanisms of electrochemotherapy. Adv. Drug Deliv. Rev. 1999;35:107–118
  45. Okino M, Mohri H. Effects of a high-voltage electrical impulse and an anticancer drug on in vivo growing tumors. Jpn. J. Cancer Res. 1987;78:1319–1321
  46. Engstrom PE, Ivarsson K, Tranberg KG, et al.  Electrically mediated drug delivery for treatment of an adenocarcinoma transplanted into rat liver. Anticancer Res. 2001;21:1817–1822
  47. Rols MP, Teissie J. Electropermeabilization of mammalian cells to macromolecules: control by pulse duration. Biophys. J. 1998;75:1415–1423
  48. Belehradek J, Orlowski S, Poddevin B, et al.  Electrochemotherapy of spontaneous mammary tumours in mice. Eur. J. Cancer. 1991;27:73–76
  49. Kuriyama S, Mitoro A, Tsujinoue H, et al.  Electrochemotherapy can eradicate established colorectal carcinoma and leaves a systemic protective memory in mice. Int. J. Oncol. 2000;16:979–985
  50. Ogihara M, Yamaguchi O. Potentiation of effects of anticancer agents by local electric pulses in murine bladder cancer. Urol. Res. 2000;28:391–397
  51. Mitoro A, Kuriyama S, Tsujinoue H, et al.  Electrochemotherapy with bleornycin against colorectal carcinoma in a mouse model: evaluations of the dose and administration route of the drug and the electric field intensity. Int. J. Oncol. 2000;16:97–104
  52. Tada T, Matsumoto K, Suzuki H. Electrochemotherapy significantly inhibits the growth of colon 26 tumors in mice. Surg. Today. 1997;27:506–510
  53. Heller R, Jaroszeski M, Perrott R, et al.  Effective treatment of B16 melanoma by direct delivery of bleomycin using electrochemotherapy. Melanoma Res. 1997;7:10–18
  54. Engstrom PE, Persson BR, Brun A, et al.  A new antitumour treatment combining radiation and electric pulses. Anticancer Res. 2001;21:1809–1815
  55. Sersa G, Beravs K, Cemazar M, et al.  Contrast enhanced MRI assessment of tumor blood volume after application of electric pulses. Electro- Magnetobiol. 1998;17:299–306
  56. Sersa G, Cemazar M, Miklavcic D, et al.  Tumor blood flow modifying effect of electrochemotherapy with bleomycin. Anticancer Res. 1999;19:4017–4022
  57. Sersa G, Cemazar M, Parkins CS, et al.  Tumour blood flow changes induced by application of electric pulses. Eur. J. Cancer. 1999;35:672–677
  58. Umezawa H, Maeda K, Takeuchi T, et al.  New antibiotics, bleomycin A and B. J. Antibiot. (Tokyo). 1966;19:200–209
  59. Mir LM, Tounekti O, Orlowski S. Bleomycin: revival of an old drug. Gen. Pharmacol. 1996;27:745–748
  60. Pron G, Mahrour N, Orlowski S, et al.  Internalisation of the bleomycin molecules responsible for bleomycin toxicity: a receptor-mediated endocytosis mechanism. Biochem. Pharmacol. 1999;57:45–56
  61. Lazo JS. Bleomycin. In:  Chabner BA editors. Cancer Chemotherapy and Biotherapy. Lippincott–Raven Publishers; 1996;p. 379–393
  62. Alberts DS, Chen H-SG, Liu R, et al.  Bleomycin pharmacokinetics in man. Cancer Chemother. Pharmacol. 1978;1:177–181
  63. Poddevin B, Orlowski S, Belehradek J, et al.  Very high cytotoxicity of bleomycin introduced into the cytosol of cells in culture. Biochem. Pharmacol. 1991;42(Suppl):S67–S75
  64. Tounekti O, Kenani A, Foray N, et al.  The ratio of single- to double-strand DNA breaks and their absolute values determine cell death pathway. Br. J. Cancer. 2001;84:1272–1279
  65. Byrnes RW, Templin J, Sem D, et al.  Intracellular DNA strand scission and growth inhibition of Ehrlich ascites tumor cells by bleomycins. Cancer Res. 1990;50:5275–5286
  66. Tounekti O, Pron G, Belehradek J, et al.  Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized. Cancer Res. 1993;53:5462–5469
  67. Burger RM. Cleavage of nucleic acids by bleomycin. Chem. Rev. 1998;98:1153–1169
  68. Lyman S, Ujjani B, Renner K, et al.  Properties of the initial reaction of bleomycin and several of its metal complexes with Ehrlich cells. Cancer Res. 1986;46:4472–4478
  69. Tounekti O, Kenani A, Foray N, et al.  The ratio of single- to double-strand DNA breaks and their absolute values determine cell death pathway. Br. J. Cancer. 2001;84:1272–1279
  70. Roy SN, Horwitz SB. Characterization of the association of radiolabeled bleomycin A2 with HeLa cells. Cancer Res. 1984;44:1541–1546
  71. Pron G, Belehradek J, Mir LM. Identification of a plasma membrane protein that specifically binds bleomycin. Biochem. Biophys. Res. Commun. 1993;194:333–337
  72. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem. 1996;65:801–847
  73. Hall SW, Strong JE, Broughton A, et al.  Bleomycin clinical pharmacology by radioimmunoassay. Cancer Chemother. Pharmacol. 1982;9:22–25
  74. Wapnir IL, Wartenberg DE, Greco RS. Three dimensional staging of breast cancer. Breast Cancer Res. Treat. 1996;41:15–19
  75. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 1989;24:148–154
  76. Heller L, Pottinger C, Jaroszeski MJ, et al.  In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity. Melanoma Res. 2000;10:577–583
  77. Mir LM, Orlowski S, Poddevin B, et al.  Electrochemotherapy tumor treatment is improved by interleukin-2 stimulation of the host’s defenses. Eur. Cytokine Netw. 1992;3:331–334
  78. Orlowski S, An D, Belehradek J, et al.  Antimetastatic effects of electrochemotherapy and of histoincompatible interleukin-2-secreting cells in the murine Lewis lung tumor. Anticancer Drugs. 1998;9:551–556
  79. Ramirez LH, Orlowski S, An D, et al.  Electrochemotherapy on liver tumours in rabbits. Br. J. Cancer. 1998;77:2104–2111
  80. Mir LM, Roth C, Orlowski S, et al.  Systemic antitumor effects of electrochemotherapy combined with histoincompatible cells secreting interleukin-2. J. Immunother. 1995;17:30–38
  81. Sersa G, Miklavcic D, Batista U, et al.  Anti-tumor effect of electrotherapy alone or in combination with interleukin-2 in mice with sarcoma and melanoma tumors. Anticancer Drugs. 1992;3:253–260
  82. Cemazar M, Miklavcic D, Sersa G. Intrinsic sensitivity of tumor cells to bleomycin as an indicator of tumor response to electrochemotherapy. Jpn. J. Cancer Res. 1998;89:328–333
  83. Sersa G, Cemazar M, Miklavcic D, et al.  Electrochemotherapy: variable anti-tumor effect on different tumor models. Bioelectrochem. Bioenerget. 1994;35:23–27
  84. Sersa G, Kotnik V, Cemazar M, et al.  Electrochemotherapy with bleomycin in SA-1 tumor-bearing mice—natural resistance and immune responsiveness. Anticancer Drugs. 1996;7:785–791
  85. Jaroszeski MJ, Illingworth P, Pottinger C, et al.  Electrically mediated drug delivery for treating subcutaneous and orthotopic pancreatic adenocarcinoma in a hamster model. Anticancer Res. 1999;19:989–994
  86. Hasegawa H, Kano M, Hoshi N, et al.  An electrochemotherapy model for rat tongue carcinoma. J. Oral Pathol. Med. 1998;27:249–254
  87. Hyacinthe M, Jaroszeski MJ, Dang VV, et al.  Electrically enhanced drug delivery for the treatment of soft tissue sarcoma. Cancer. 1999;85:409–417
  88. Horiuchi A, Nikaido T, Mitsushita J, et al.  Enhancement of antitumor effect of bleomycin by low-voltage in vivo electroporation: a study of human uterine leiomyosarcomas in nude mice. Int. J. Cancer. 2000;88:640–644
  89. Mir LM, Roth C, Orlowski S, et al.  Potentiation of the antitumoral effect of electrochemotherapy by immunotherapy with allogeneic cells producing interleukin 2. C. R. Acad. Sci. III. 1992;314:539–544
  90. Heller R, Jaroszeski M, Leo-Messina J, et al.  Treatment of B16 mouse melanoma with the combination of electropermeabilization and chemotherapy. Bioelectrochem. Bioenerget. 1995;36:83–87
  91. Jaroszeski MJ, Gilbert R, Perrott R, et al.  Enhanced effects of multiple treatment electrochemotherapy. Melanoma Res. 1996;6:427–433
  92. Yamaguchi O, Irisawa C, Baba K, et al.  Potentiation of antitumor effect of bleomycin by local electric pulses in mouse bladder tumor. Tohoku J. Exp. Med. 1994;172:291–293
  93. Engstrom PE, Persson BR, Salford LG. Dynamic gamma camera studies of 111-In–bleomycin complex in normal and glioma bearing rats after in vivo electropermeabilization using exponential high-voltage pulses. Bioelectrochem. Bioenerget. 1998;46:241–248
  94. Chazal M, Benchimol D, Baque P, et al.  Treatment of hepatic metastases of colorectal cancer by electrochemotherapy: an experimental study in the rat. Surgery. 1998;124:536–540
  95. Salford LG, Persson BR, Brun A, et al.  A new brain tumour therapy combining bleomycin with in vivo electropermeabilization. Biochem. Biophys. Res. Commun. 1993;194:938–943
  96. Jaroszeski MJ, Gilbert RA, Heller R. In vivo antitumor effects of electrochemotherapy in a hepatoma model. Biochim. Biophys. Acta. 1997;1334:15–18
  97. Mir LM, Devauchelle P, Quintin-Colonna F, et al.  First clinical trial of cat soft-tissue sarcomas treatment by electrochemotherapy. Br. J. Cancer. 1997;76:1617–1622
  98. Heller R. Treatment of cutaneous nodules using electrochemotherapy. J. Fla. Med. Assoc. 1995;82:147–150
  99. Panje WR, Hier MP, Carman GR, et al.  Electroporation therapy of head and neck cancer. Ann. Otol. Rhinol. Laryngol. 1998;107:779–785
  100. Glass LF, Fenske NA, Jaroszeski M, et al.  Bleomycin-mediated electrochemotherapy of basal cell carcinoma. J. Am. Acad. Dermatol. 1996;34:82–86
  101. Glass LF, Jaroszeski M, Gilbert R, et al.  Intralesional bleomycin-mediated electrochemotherapy in 20 patients with basal cell carcinoma. J. Am. Acad. Dermatol. 1997;37:596–599

PII: S0305-7372(03)00073-2

doi: 10.1016/S0305-7372(03)00073-2

Cancer Treatment Reviews
Volume 29, Issue 5 , Pages 371-387 , October 2003

Article Tools